The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Share News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Open Orphan CEO Steps Down; Inks New Challenge Study Contract

Mon, 04th May 2020 14:35

(Alliance News) - Open Orphan PLC on Monday announced that Chief Executive Trevor Phillips will be standing down and said it has signed a new contract with a US biotechnology.

Shares in the pharmaceutical services firm were up 10% at 9.90 pence in London in afternoon trading.

Philips will stay in his role until June end but has departed the board with immediate effects. He joined hVIVO at the end of 2018 and led hVIVO's merger with Open Orphan. Executive Chair Cathal Friel will lead Open Orphan.

The new contract is for Open Orphan to provide a human challenge study in respiratory syncytial virus, a highly contagious viral disease and among the most common causes of pneumonia and bronchiolitis. Challenge studies purposefully expose healthy volunteers to an infectious disease.

The biotechnology company's name was not disclosed, though Open Orphan expects to receive around GBP3.5 million of revenue in 2020 from the study.

Open Orphan acquired Venn Life Sciences Holdings PLC in January, the same month its completed its merger with hVIVO PLC. The study will use the clinical research organisation services of hVIVO and Venn and will take place at hVIVO's London-based quarantine unit in the third quarter of 2020.

Friel said: "Firstly, I would like to thank Trevor for his help merging Open Orphan and hVIVO. Trevor had previously successfully right sized and focused hVIVO and our refreshed management team is now focused on delivering growth at a very exciting time for the company.

"The signing of this new GBP3.5 million contract with a US biotechnology company is further evidence of this exciting time as we successfully convert Open Orphan's pipeline of prospects into formal customer contracts. Open Orphan will be utilising its complementary in-house [clinical research organisation] services of hVIVO and Venn to deliver this contract. This contract demonstrates the Open Orphan and hVivo group's focus on building long term contracts with recurring revenues to deliver future profitability while ensuring rationalising the business and reduce costs."

By Anna Farley; annafarley@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
15 Nov 2021 11:32

Open Orphan subsidiary secures contract renewal with 'major' pharmaceutical client

(Sharecast News) - Contract research organisation Open Orphan said on Monday that its Venn Life Sciences subsidiary had signed a contract renewal with an unnamed "major global pharmaceutical client" worth £1.5m over a two-year period.

Read more
13 Oct 2021 13:25

EXECUTIVE CHANGES: Halfords hires CFO; new Pendragon, Versarien chairs

EXECUTIVE CHANGES: Halfords hires CFO; new Pendragon, Versarien chairs

Read more
20 Sep 2021 14:30

Open Orphan signs £5.7m contract with biotech specialist

(Sharecast News) - Clinical research organisation Open Orphan announced on Monday that its subsidiary hVIVO has signed a £5.7m contract with a specialist biotechnology company developing therapeutics for respiratory viral infections, to test its antiviral product using the hVIVO Influenza human challenge study model.

Read more
20 Sep 2021 12:02

TRADING UPDATES: Christie Group and Open Orphan swing to profit

TRADING UPDATES: Christie Group and Open Orphan swing to profit

Read more
13 Sep 2021 16:11

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
7 Sep 2021 18:16

TRADING UPDATES: Victoria growth continues; Renew to beat consensus

TRADING UPDATES: Victoria growth continues; Renew to beat consensus

Read more
7 Sep 2021 14:59

TRADING UPDATES: Marlowe buys Santia; Gaming Realms notes new launch

TRADING UPDATES: Marlowe buys Santia; Gaming Realms notes new launch

Read more
24 Aug 2021 11:41

AIM WINNERS & LOSERS: Open Orphan rises on asthma study contract win

AIM WINNERS & LOSERS: Open Orphan rises on asthma study contract win

Read more
24 Aug 2021 09:31

Open Orphan shares lift on GBP8.1 million asthma study contract win

Open Orphan shares lift on GBP8.1 million asthma study contract win

Read more
9 Aug 2021 17:08

TRADING UPDATES: Netcall wins new deal; Sareum raises GBP1 million

TRADING UPDATES: Netcall wins new deal; Sareum raises GBP1 million

Read more
22 Jul 2021 10:49

AIM WINNERS & LOSERS: Restore rises as it rebuffs Marlowe approach

AIM WINNERS & LOSERS: Restore rises as it rebuffs Marlowe approach

Read more
14 Jul 2021 16:15

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
14 Jul 2021 15:07

IN BRIEF: Open Orphan study grows, spinoff worth GBP50 million at IPO

IN BRIEF: Open Orphan study grows, spinoff worth GBP50 million at IPO

Read more
14 Jul 2021 15:01

IN BRIEF: Open Orphan team invests GBP350,000 as spin-off set to debut

IN BRIEF: Open Orphan team invests GBP350,000 as spin-off set to debut

Read more
14 Jul 2021 09:10

Open Orphan secures €900,000 contract with existing customer

(Sharecast News) - Pharmaceutical services company Open Orphan has secured a new contract win with an unnamed existing customer.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.